1. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Issue 12 (December 2015) Authors: Richardson, Paul G; Jagannath, Sundar; Moreau, Philippe; Jakubowiak, Andrzej J; Raab, Marc S; Facon, Thierry; Vij, Ravi; White, Darrell; Reece, Donna E; Benboubker, Lotfi; Zonder, Jeffrey; Tsao, L Claire; Anderson, Kenneth C; Bleickardt, Eric; Singhal, Anil K; Lonial, Sagar Journal: Lancet Issue: Volume 2:Issue 12(2015) Page Start: e516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗